{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:48Z","timestamp":1792587768582,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12325-015-0221-5","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T11:51:25Z","timestamp":1436356285000},"page":"637-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms"],"prefix":"10.1007","volume":"32","author":[{"given":"Fiona","family":"McPhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Karino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiiku","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafia","family":"Bhore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,9]]},"reference":[{"key":"221_CR1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology. 2014;59:318\u201327.","journal-title":"Hepatology"},{"key":"221_CR2","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","volume":"20","author":"F Ansaldi","year":"2014","unstructured":"Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20:9633\u201352.","journal-title":"World J Gastroenterol"},{"key":"221_CR3","unstructured":"World Health Organization. Hepatitis C Key Facts. WHO factsheet No 164. 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ . Accessed Apr 2015."},{"key":"221_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96\u2013100.","journal-title":"Nature"},{"key":"221_CR5","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","volume":"60","author":"AS Lok","year":"2014","unstructured":"Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60:490\u20139.","journal-title":"J Hepatol"},{"key":"221_CR7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655\u201362.","journal-title":"J Hepatol"},{"key":"221_CR8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"221_CR9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597\u2013605.","journal-title":"Lancet"},{"issue":"suppl","key":"221_CR10","first-page":"1135A","volume":"60","author":"K Chayama","year":"2014","unstructured":"Chayama K, Suzuki F, Suzuki Y, et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus peginterferon alfa\/ribavirin in treatment-naive Japanese patients chronically infected with HCV genotype 1b: results from a phase 3 study. Hepatology. 2014;60(suppl):1135A.","journal-title":"Hepatology"},{"key":"221_CR11","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","volume":"13","author":"MJ Alter","year":"2007","unstructured":"Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436\u201341.","journal-title":"World J Gastroenterol"},{"key":"221_CR12","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.1840360724","volume":"36","author":"TL Wright","year":"2002","unstructured":"Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36:S185\u201394.","journal-title":"Hepatology"},{"key":"221_CR13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.20984","volume":"43","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43:54\u201363.","journal-title":"Hepatology"},{"key":"221_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","volume":"12","author":"S Pol","year":"2012","unstructured":"Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype 1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12:671\u20137.","journal-title":"Lancet Infect Dis"},{"key":"221_CR15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58:902\u201311.","journal-title":"Hepatology"},{"key":"221_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","volume":"19","author":"F McPhee","year":"2014","unstructured":"McPhee F, Hernandez D, Zhou N, et al. Virological escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther. 2014;19:479\u201390.","journal-title":"Antivir Ther"},{"key":"221_CR17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646\u201354.","journal-title":"J Hepatol"},{"key":"221_CR18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1386-6346(00)00074-7","volume":"18","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res. 2000;18:252\u201366.","journal-title":"Hepatol Res"},{"key":"221_CR19","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","volume":"313","author":"F Poordad","year":"2015","unstructured":"Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728\u201335.","journal-title":"JAMA"},{"key":"221_CR20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","volume":"313","author":"AJ Muir","year":"2015","unstructured":"Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736\u201344.","journal-title":"JAMA"},{"key":"221_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u201321.","journal-title":"N Engl J Med"},{"key":"221_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40121-014-0052-8","volume":"4","author":"J Friborg","year":"2015","unstructured":"Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with Hepatitis C Virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2015;4:137\u201344.","journal-title":"Infect Dis Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0221-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:20:06Z","timestamp":1498231206000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0221-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0221-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}